StreetInsider.com News Articles

Ginkgo Bioworks (DNA) 4K contracts of December 11 calls trade, share price up 15%

Thu, 17 Sep 2026 15:19:51 -0400

Ginkgo Bioworks (NYSE: DNA) 30-day option implied volatility is at 92; compared to its 52-week range of 76 to 183 with a focus on 4K contracts of December 11 calls trading at 60c as share price up 15%.

Ginkgo Bioworks (DNA) 4K contracts of December 11 calls trade, share price up 13.3%

Thu, 17 Sep 2026 15:11:01 -0400

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Thu, 17 Sep 2026 09:53:00 -0400

si-local-file:///var/storage/secattach/20260917/27073946.html

Form 4 Ginkgo Bioworks Holdings For: Sep 15 Filed by: HENRY CHRISTIAN O

Wed, 16 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260916/27070317.html

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Wed, 16 Sep 2026 09:52:00 -0400

Integration puts Ginkgo’s biological data generation services at the heart of the industry’s most prominent AI-driven drug discovery network

BOSTON--(BUSINESS WIRE)-- Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data.

Ginkgo Datapoints will provide discovery data generation services, including small molecule developability (ADME) and antibody

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Wed, 16 Sep 2026 09:52:00 -0400

Integration puts Ginkgo’s biological data generation services at the heart of the industry’s most prominent AI-driven drug discovery network

Ginkgo Datapoints will provide discovery data generation services, including small molecule developability (ADME) and antibody

Form 144 Ginkgo Bioworks Holdings Filed by: HENRY CHRISTIAN O

Tue, 15 Sep 2026 11:48:00 -0400

si-local-file:///var/storage/secattach/20260915/27063566.html

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Thu, 10 Sep 2026 08:00:00 -0400

Ginkgo plans to build the automation hardware and control software for ESCALATOR, a continuous-flow, autonomous manufacturing system designed to produce and quality-release RNA drug products at patient scale

BOSTON--(BUSINESS WIRE)-- Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a multi-organization effort to compress

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Thu, 10 Sep 2026 08:00:00 -0400

Ginkgo Bioworks Holdings Inc (DNA) PT Lowered to $5 at BTIG

Wed, 09 Sep 2026 05:54:37 -0400

BTIG analyst Mark A. Massaro lowered the price target on Ginkgo Bioworks Holdings Inc (NYSE: DNA) to $5.00 (from $9.00) while maintaining a Sell rating.

The analyst comments "In this note, we update our Ginkgo model following
the company's Q4 call. Ginkgo is now focusing its business on Autonomous Labs,
which they will build out here in 2026 and plans to increase its RAC cart automation
(acquired from Zymergen in 2022) in its Boston facility from 50 to 100 systems by
YE'2026. 2026 appears to be yet another transition year for Ginkgo, in our view, given
its recently announced (1) divestiture

Ginkgo Bioworks Holdings Inc (DNA) PT Lowered to $5 at BTIG

Wed, 09 Sep 2026 05:54:37 -0400

BTIG analyst Mark A. Massaro lowered the price target on Ginkgo Bioworks Holdings Inc (NYSE: DNA) to $5.00 (from $9.00) while maintaining a Sell rating.

BTIG Reiterates Sell Rating on Ginkgo Bioworks Holdings Inc (DNA)

Fri, 04 Sep 2026 06:12:55 -0400

BTIG analyst Mark A. Massaro reiterated a Sell rating and $5.00 price target on Ginkgo Bioworks Holdings Inc (NYSE: DNA).

The analyst commented: "We recently had an opportunity to meet with Ginkgo's CEO and CFO and tour Ginkgo's Nebula, which Ginkgo asserts is the largest autonomous lab in the world. Ginkgo recently increased the number of its RAC carts in Nebula from 50 to 105, and is proud it accomplished the expansion in a period of just three weeks. We acknowledge the concept of autonmous labs is pretty cool - far fewer scientists are needed to perform manual bench work, work

Form 4 Ginkgo Bioworks Holdings For: Aug 21 Filed by: Coen Steven P.

Tue, 25 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260825/26975569.html

Form 4 Ginkgo Bioworks Holdings For: Aug 21 Filed by: Coen Steven P.

Tue, 25 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260825/26975569.html

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Mon, 24 Aug 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26967821.html

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Mon, 24 Aug 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260824/26967821.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Mon, 17 Aug 2026 12:18:00 -0400

si-local-file:///var/storage/secattach/20260817/26936897.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Mon, 17 Aug 2026 12:18:00 -0400

si-local-file:///var/storage/secattach/20260817/26936897.html

TD Cowen Downgrades Ginkgo Bioworks Holdings Inc (DNA) to Hold

Fri, 07 Aug 2026 02:07:23 -0400

TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks Holdings Inc (NYSE: DNA) from Buy to Hold with a price target of $9.00 (from $12.00).

The analyst comments: “Ginkgo is in the midst of a key transformation period that requires continued investment in both capital and time to achieve the autonomous and data-forward vision they are aiming for over the next few years. The pivot to a focus on Datapoints and Autonomous Labs has merit but will take time to reap the benefit of ongoing investments and manufacturing expansion. In the meantime, near-term growth of the company's legacy Solutions segment alone remains

TD Cowen Downgrades Ginkgo Bioworks Holdings Inc (DNA) to Hold

Fri, 07 Aug 2026 02:07:23 -0400

TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks Holdings Inc (NYSE: DNA) from Buy to Hold with a price target of $9.00 (from $12.00).

Form 10-Q Ginkgo Bioworks Holdings For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883935.html

Form 10-Q Ginkgo Bioworks Holdings For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883935.html

Ginkgo Bioworks (DNA) Tops Q2 EPS by 13c

Wed, 05 Aug 2026 17:29:49 -0400

Ginkgo Bioworks (NYSE: DNA) reported Q2 EPS of ($0.92), $0.13 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $20 million versus the consensus estimate of $29.9 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.

Form 8-K Ginkgo Bioworks Holdings For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874041.html

Form 8-K Ginkgo Bioworks Holdings For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874041.html